DECTREKUMAB
Idiopathic Pulmonary Fibrosis
Novartis Pharmaceuticalsmonoclonal_antibodyPhase 2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 73/ 100
Competitive context
111 Active assets in the Idiopathic Pulmonary Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pirfenidone Endeavor Biomedicines, Inc. | Phase 4 | A |
N-Acetyl-L-Cysteine Endeavor Biomedicines, Inc. | Phase 4 | BBB |
Nintedanib Mannkind Corporation | Phase 4 | BBB |
PREDNISONE TABLETS Fondation Hôpital Saint-Joseph | Phase 3 | BB |
hsk44459 Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
DECTREKUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →